Effectiveness of a Group B Omv Meningococcal Vaccine on Gonorrhoea in New Zealand – a Case Control Study
Helen Petousis-Harris, BSc, PhD1, Janine Paynter, BSc, MSc, PhD2, Jane Morgan, MBChB, MD3, Peter Saxton, PhD4, Jill Sherwood, MBChB, MPH5, Barbara McArdle, BHSc, MCE6, Felicity Goodyear-Smith, MBChB, MD, FRNZCGP2, Joanna Stewart, MSc7 and Steve Black, MD8, 1Department of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand, 2Department of General Practice and Primary Health Care, Univeristy of Auckland, Auckland, New Zealand, 3Waikato District Health Board, Waikato Sexual Health Clinic, Hamilton, New Zealand, 4Gay Men's Sexual Health, University of Auckland, Auckland, New Zealand, 5Health Science, Institute of Environmental Science and Research Ltd, Porirua, New Zealand, 6Department General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand, 7Department of Biostatistics and Epidemiology, University of Auckland, Auckland, New Zealand, 8Department of Pediatrics,, University of Cincinnati Children’s Hospital, Ohio, OH